checkAd

     125  0 Kommentare SHS Viveon: Subdued first half – revenue outlook downgraded – PT down; BUY

    In H1, SHS experienced some headwinds from challenging market conditions as well as from shortages in the project-based business.

    The full update is avaible on:

    Read

     

    What's it all about ?

    In H1, SHS experienced some headwinds from challenging market conditions as well as from shortages in the project-based business. These challenging market conditions caused customer restraint and longer decision cycles regarding new contracts. Further, project-based revenues declined sharply due to capacity shortages, although demand for project services was positive. However, a slower pace of investments will support the improved profit guidance. Hence, we model a part of investments to move into later periods. We project a lower growth trajectory and lower our PT slightly to EUR 15.00 (old: EUR 15.50). Our recommendation remains BUY.

    https://www.research-hub.de/disclaimer

    Die SHS VIVEON Aktie wird zum Zeitpunkt der Veröffentlichung der Nachricht mit einem Plus von +8,99 % und einem Kurs von 4,12EUR auf Tradegate (24. August 2022, 12:57 Uhr) gehandelt.

    Diskutieren Sie über die enthaltenen Werte


    AlsterResearch AG
    0 Follower
    Autor folgen
    Mehr anzeigen
    Bei der AlsterResearch AG handelt es sich um ein unabhängiges (Aktien)-Analysehaus mit Fokus auf deutschen Nebenwerten (Small & MidCaps).
    Mehr anzeigen

    Verfasst von AlsterResearch AG
    SHS Viveon: Subdued first half – revenue outlook downgraded – PT down; BUY In H1, SHS experienced some headwinds from challenging market conditions as well as from shortages in the project-based business. These challenging market conditions caused customer restraint and longer decision cycles regarding new contracts. Further, project-based revenues declined sharply due to capacity shortages, although demand for project services was positive. However, a slower pace of investments will support the improved profit guidance.